Journals / Türk Kardiyoloji Derneği Arşivi / 2019 / Cilt: 47 - Sayı: 5

Short term follow-up of a patient with uncomplicated type B aortic dissection under dabigatran treatment

Dabigatran kullanımı altında komplike olmayan tip B aort diseksiyonlu hastanın kısa dönem takibi

Pages
413–416
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on this case, the use of dabigatranwould appear to be safe in a patient with an uncomplicatedtype B AD, but the results of this case need to be confirmedwith extended follow-up and additional patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This case report illustrates the follow-up of a57-year-old female with a type B aortic dissection (AD) underdabigatran treatment.
📊
Key Findings & Data:The patient had been operatedon 8 years earlier due to type A AD.
💡
Conclusion & Impact:Based on this case, the use of dabigatranwould appear to be safe in a patient with an uncomplicatedtype B AD, but the results of this case need to be confirmedwith extended follow-up and additional patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This case report illustrates the follow-up of a57-year-old female with a type B aortic dissection (AD) underdabigatran treatment. The patient had been operatedon 8 years earlier due to type A AD. The aortic valve wasrepaired and a 26-mm polyester fiber graft was applied tothe ascending aorta and the aortic arch. In computerizedtomography scans taken after the procedure, a dissectionflap extending from the descending aorta to the iliac arterieswas seen, but the patient was asymptomatic and no furthersurgery was performed. The patient was subsequently diagnosedwith atrial fibrillation. A CHA₂DS₂VASc score of 3 wasrecorded and dabigatran treatment was initiated. The aorticaneurysm and dissection were followed up via computed tomographyand echocardiography at regular intervals, and at6 months no progression was seen. No thromboembolic orhemorrhagic events were observed. To our knowledge, thisis the first case report of dabigatran treatment for a patientwith a type B AD. Based on this case, the use of dabigatranwould appear to be safe in a patient with an uncomplicatedtype B AD, but the results of this case need to be confirmedwith extended follow-up and additional patients.

Özet

Bu olgu sunumunda tip B aort diseksiyonu tanılı 57 yaşında bir kadın hastanın atriyal fibrilasyon nedenli başlanan dabigatran tedavisi altında takibi özetlendi. Hastanın tip A diseksiyon nedenli 8 yıl önce aort kapak tamiri ve çıkan aorta ve aortik arkta dakron greft implantasyonu hikayesi vardı. Cerrahiden sonraki bilgisayarlı tomografi incelemelerinde inen aorttan iliyak arterlere uzanan bir diseksiyon flebi görülmüş, ancak hasta semptomsuz olduğundan tekrar ameliyat edilmemişti. Hastanın 6 ay önce tarafımıza başvurusunda atriyal fibrilasyon tanısı kondu. CHA₂DS₂VASc skoru 3 olan hastaya dabigatran tedavisi başlandı. Hastanın aort anevrizma ve diseksiyonu ekokardiyografi ve bilgisayarlı tomografi ile 6 ay takip edildi ve bu süreçte hastanın diseksiyon hattında ilerleme veya embolik/hemorajik komplikasyon görülmedi. Yaptığımız literatür taramasına göre bu olgu sunumu dabigatran tedavisi altında tip B aort diseksiyonu takibi yapılan ilk olgudur. Bu olgu neticesinde dabigatran kullanımının komplikasyonsuz tip B aort diseksiyonunda güvenli olabileceği sonucuna varılmıştır. Daha net bir sonuca varmak için daha uzun takipli daha çok olgu içeren çalışmalar gerekmektedir.

🔖

Cite This Article

Akşit, E., Yıldırım, Ö. T., Çanakçı, M. E., Aydın, A. H., Aydın, F. (2022). Short term follow-up of a patient with uncomplicated type B aortic dissection under dabigatran treatment. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 5, 413–416. https://ajindex.com/articles/632109

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873–926
  2. Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, et al; INSTEAD Trial. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation 2009;120:2519–28
  3. Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, et al; INSTEAD-XL trial. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013;6:407–16
  4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962
  5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62
  6. Leow AS, Sia CH, Tan BY, Loh JP. A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. J Thromb Thrombolysis 2018;46:68–73
  7. Smetana KS, Dunne J, Parrott K, Davis GA, Collier ACS, Covell M, et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis 2017;44:519–24
  8. Bahmaid R, Ammar S, Al-Subaie S, Soofi M, Mhish H, Yahia M. Efficacy of target specific oral anticoagulants on the resolution of left ventricular thrombus: Case Series. Surg Case Rep Rev 2018;2:1-5
  9. Aydin F, Turgay Yildirim O, Huseyinoglu Aydin A, Dagtekin E, Aksit E. Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report. J Stroke Cerebrovasc Dis 2018;27:e203–e205
  10. Abubakar H, Shokr M, Subahi A, Rashed A. Reduced dose apixaban resolving dual cardiac chamber thrombi in a patient with ischaemic cardiomyopathy in sinus rhythm. BMJ Case Rep 2017;2017. pii: bcr-2017